Roivant Sciences Ltd. reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported revenue was USD 37.14 million compared to USD 17.05 million a year ago. Net income was USD 5,096.18 million compared to net loss of USD 352.01 million a year ago. Basic earnings per share from continuing operations was USD 6.37 compared to basic loss per share from continuing operations of USD 0.49 a year ago. Diluted earnings per share from continuing operations was USD 6.03 compared to diluted loss per share from continuing operations of USD 0.49 a year ago.
For the nine months, revenue was USD 95.87 million compared to USD 33.9 million a year ago. Net income was USD 4,500.04 million compared to net loss of USD 975.41 million a year ago. Basic earnings per share from continuing operations was USD 5.79 compared to basic loss per share from continuing operations of USD 1.39 a year ago. Diluted earnings per share from continuing operations was USD 5.46 compared to diluted loss per share from continuing operations of USD 1.39 a year ago.